

An additional patient has been treated in Toronto, Canada

Another patient in the SpectraCure Phase 1 study has been treated for relapse of prostate cancer at Princess Margaret Cancer Centre in Toronto, Canada. The treatment went well and the SpectraCure technology worked according to plan. There are a number of patients on the waiting list waiting for treatment. The procedure used SpectraCures IDOSE® technology for treatment planning and to deliver the laser light dose to the cancer tumour. The treatment method, called Photodynamic therapy (PDT), means that the patient is given a light-activated drug that accumulates in the tumour. When the cancer tissue is illuminated by laser light of the correct wavelength, the drug is activated and knocks out the tumour. The procedure places high demands on accurate control of the laser light dose.

The treatment was performed by the same medical team as before at the urology clinic at the hospital in Toronto, with technical support from the SpectraCure staff.

- It has been intensive work with patient recruitment along with the medical team. We look forward with great anticipation to future treatments in Phase 1, comments SpectraCure CEO Masoud Khayyami.

During the first part of the Phase 1 study, the clinical protocol requires a follow-up period of at least one month between treatments. In the latter part of the study, starting in the autumn of 2017, several patient treatments can be performed during a short period of time. Thus, the pace is anticipated to accelerate. The treatments in the Phase 1 study will continue for the remainder of 2017. After the final treatment in Phase 1, a continuation of a Phase 2 study is foreseen, in which a group of patients will be treated with the treatment dose established in Phase 1.

The Phase 1 study refers to the treatment of patients receiving relapse of prostate cancer after having had radiotherapy. For this patient group, there are no curative treatment options in routine care, and they are normally referred to hormonal treatment to inhibit tumour growth. Hormonal treatment often causes undesirable side effects. SpectraCure aims to offer a curative treatment option for these patients, with fewer and less severe side effects.

For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.